Longevity Science Company Human Edge Raises Over $1.5M Capital

Human Edge, a longevity science company, has announced that it has raised over USD 1.5M in new equity financing. The investment was led by Bharat Innovation Fund, along with Lead Angels and Force Ventures and a number of strategic angel investors from Singapore, USA, and India.  

Human Edge approaches longevity via enhancing healthspan using science, deep data and technology-based lifestyle interventions. The company is building a proprietary platform for empowering its users to engage in daily “biohacks”- small, actionable, lifestyle based modifications that focus on optimizing a person’s energy levels towards meeting a specific health outcome. These biohack “prescriptions'' are personalised based on a user sharing data with the Human Edge platform which is a combination of assessments, blood panels and real time digital streams from consumer tech wearables like the Oura ring, Abbott’s Continuous Glucose Monitor, Apple Watch, Fitbit band and many more. This data is cumulated to generate a composite healthspan score, called the 'Human Edge Index'.  

Speaking on behalf of Bharat Innovation Fund, an India based deep tech fund that led the round, Cofounder and Partner Ashwin Raguraman said, “The human body generates a tremendous amount of data, which if used effectively to modify our behaviour, can lead to a better quality of life. The proliferation of wearable devices means that we now have access to data. Human Edge’s technology enables us to interpret that data effectively and provides each of us with a clear call to action on that data, to improve our metabolic health and overall well-being. We are delighted that our partnership with Human Edge helps us support Dr Marcus Ranney bring his pioneering work in high performance environments to a larger audience and  provide clinically backed actionable insights to help improve lifestyles of  people across the world”. 

The investment will allow Human Edge to streamline their platform through its first enterprise-wide mobile app experience targeted directly at the white-collar employees. Further, the company will scale up their sales in the international market by targeting global corporations. Ashika Capital was an advisor to Human Edge in this process, the company said in a statement. 

“The simple focus of our efforts is on democratizing health by facilitating each of us to live at our most optimal self, moving beyond the more traditional disease focused outcomes. We, at Human Edge, chose to focus on energy as each of us would like to optimize our energy levels each day to achieve the goals we set out for ourselves”, says Dr. Marcus Ranney, Founder & CEO, Human Edge. 

The global biohacking market currently stands at over USD 15 billion—and is expected to grow at a CAGR of 19 per cent. Moreover, the rapidly growing wearables market–which was worth well over USD 100 billion in 2021 also creates an ecosystem that allows Human Edge to provide deep insights to individuals, based on their own real-time health data coming from such wearables, to personalize their health journeys. Improving recovery, bettering one’s metabolic health, enhancing endurance, and gaining sharper focus are just some of the many health outcomes Human Edge users work towards. 

Commenting on the business opportunity for Human Edge, Ashwin Raguraman further added; “With the focus shifting to preventive healthcare and wellness, there is a greater awareness of the strong linkage between productivity and metabolic health. Employers have recognized that the wellbeing of their workforce is paramount to optimizing their performance. Human Edge’s solutions, deeply rooted in clinical science, and providing their customers with the ability to enhance the overall health of the organization makes for a compelling value proposition.”  

The global corporate wellness market is expected to cross the value of USD 74.5 Billion by the end of 2028, as per industry reports. Rise in awareness about health and wellness among employers & employees and increase in incidence of chronic conditions are anticipated to propel the global market.